Cipla reported a 54.6% drop in fourth-quarter net profit to 5.55 billion rupees ($58 million) as North American sales slumped and missed analyst estimates. The result trailed the 7.05 billion rupee average forecast by LSEG. Weak U.S. margins and higher costs offset strong domestic growth, signaling a geographic shift in the drugmaker's profit drivers.

North American Slump Offsets Domestic Growth